The national basic inventory of high-performance medical devices can only be solved by consulting relevant materials. According to years of learning experience, if we solve the basic inventory of national high-performance medical devices, we can get twice the result with half the effort. Let's share the relevant methods and experiences of the national basic inventory of high-performance medical devices for your reference.
National high-performance medical equipment base unit
The national special project of basic materials for high-performance medical devices (202 1YFB0303202) was released on 20021. Please note that investment is risky, so please choose carefully.
The state supports medical and pharmaceutical units.
The state has no policy of directly supporting or encouraging medical and pharmaceutical units.
However, the government has been improving China's medical system by providing medical subsidies, supporting the research and development of innovative drugs and encouraging hospital reform. At the same time, the government also encourages and supports the development of Chinese medicine, so as to promote the traditional culture of China and protect national health. These policies and measures are aimed at improving medical services and improving people's health, rather than directly supporting medical and pharmaceutical units.
In short, although the government supports the medical field to a certain extent, it does not directly encourage or support the policies of medical and pharmaceutical units.
National medical laboratory concept stocks
National medical laboratory concept stocks include:
_ _ Guan Hao creature.
_ _ Wei Lan Medicine.
_ _ Kangtai Medicine.
_ _ mike biological.
_ _ Daan gene.
_ _ Bi Shuiyuan.
_ _ Huada Gene.
_ _ Huatai Securities.
_ _ Zhongyuan Concord.
_ _ palm reading technology.
_ _ Huaping shares.
_ _ Bi Shuiyuan.
_ _ Zhongke Information.
_ _ Haichang new materials.
_ _ Changshan Pharmaceutical.
_ _ Aolian Electronics.
_ _ Mingde creature.
_ _ Nantian Information.
_ _ Entrepreneurship Huixun.
_ _ Dazhi Technology.
_ _ Saisheng Pharmaceutical.
_ _ Changyang Technology.
_ _ Entrepreneurship Huixun.
_ _ million bonds.
_ _ He Shan Fu Yao.
_ _ Nobon shares.
_ _ Ha Sanlian.
_ _ Opening medical services.
_ _ Haichuang Pharmaceutical.
_ _ Novezan.
_ _ Emerging industries.
_ _ Wan Tai creature.
_ _ mike biological.
_ _ Mingde creature.
_ _ Nantian Information.
_ _ Haichang new materials.
_ _ Changshan Pharmaceutical.
_ _ Aolian Electronics.
_ _ Bi Shuiyuan.
_ _ Zhongke Information.
_ _ Haichuang Pharmaceutical.
_ _ Novezan.
_ _ Emerging industries.
_ _ Wan Tai creature.
_ _ mike biological.
_ _ Mingde creature.
_ _ Nantian Information.
_ _ Haichang new materials.
_ _ Changshan Pharmaceutical.
_ _ Aolian Electronics.
_ _ Bi Shuiyuan.
_ _ Zhongke Information.
_ _ Haichuang Pharmaceutical+Sub-new shares: Kangtai Pharmaceutical, mike biological, Mingde Bio, Zhang Yue Science and Technology, Bi Shuiyuan, Nantian Information, Harbin Sanlian, Giant Panda Kaikai Medical, Wanbangde, He Shan Yaofu, Nuobang, Bi Shuiyuan, Zhongke Information, Haichuang Pharmaceutical, Nuoherui, New Industry, Wan Tai Bio, mike biological, Mingde Bio, Nantian Information, Haichang New Materials, etc.
National medical prevention and control concept stocks
National medical prevention and control concept stocks include the following companies:
_ _ _ _ _ _ Everbright Jiabao (600622): _ _ The company intends to transfer its 5 1% equity of Everbright Jinmao (Shanghai) Co., Ltd. to the controlling shareholder Everbright Group by non-public agreement.
_ _ _ _ _ _ Great Wall Motor (601633): _ _ Company is accelerating the layout of hydrogen energy industry, and plans to realize the adaptation of hydrogen energy technology for its products by 2025, and build hydrogen refueling stations in Beijing, Shanghai and other places.
_ _ _ _ _ Huada Gene (300676): _ _ The company plans to purchase 0/00% equity of Huada Zhizao/KLOC by issuing shares, thus expanding the business scope of Huada Gene.
_ _ _ _ Zhongxin Chemical Industry (300037): _ _ In response to the strict control of hazardous chemicals by the state, the company is actively studying the synthesis technology of new source products (high-end pharmaceutical intermediates and heterocyclic pharmaceutical raw materials).
_ _ _ _ _ _ Yaben Chemical (300261): Nanjing Youtuo Biotechnology Co., Ltd., a wholly-owned subsidiary of _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ Medical Stone Science and Technology (300799): _ _ Company is developing the synthesis process of pharmaceutical intermediates pyruvate and polyether ketone, which can be used to produce therapeutic drugs in COVID-19.
_ _ _ _ _ _ Stelli(603555):_ _ _ The holding subsidiary of _ _ _ Company has started to provide a small amount of direct alcohol-soluble polymer materials to some domestic designated production units of therapeutic drugs in COVID-19, which can be used for the production of therapeutic drugs in COVID-19.